Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease by Persson, Frederik et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease
Persson, Frederik; Frimodt-Møller, Marie; Rossing, Peter
Published in:
Kidney International Reports
DOI:
10.1016/j.ekir.2019.08.009
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Persson, F., Frimodt-Møller, M., & Rossing, P. (2019). Inflammation Leads the Way on the ROADMAP to
Diabetic Kidney Disease. Kidney International Reports, 4(10), 1362-1365.
https://doi.org/10.1016/j.ekir.2019.08.009
Download date: 03. Feb. 2020
COMMENTARYInﬂammation Leads
the Way on the ROADMAP
to Diabetic Kidney Disease
Frederik Persson1, Marie Frimodt-Møller1 and Peter Rossing1,2
1Steno Diabetes Center Copenhagen, Gentofte, Denmark; and 2Department of Clinical
Medicine, University of Copenhagen, Copenhagen Denmark
Kidney Int Rep (2019) 4, 1362–1365; https://doi.org/10.1016/j.ekir.2019.08.009
ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).See Clinical Research on Page 1373W orldwide, 425 million in-dividuals or 1 in 11 has
diabetes, and projections suggest a
48% increase by 2045 to 629
million people, according to the
International Diabetes Federation,
and whenever projections are
updated, the numbers are
increased. Treatment of diabetes
and chronic kidney disease in
diabetes has improved with mul-
tiple risk factor control, including
blood glucose and blood pressure,
including blockade of the renin
angiotensin system with signiﬁ-
cant improvements in outcome.1
US national survey data demon-
strated a 28% reduction in risk for
end-stage renal disease (ESRD) for
the individual patient from 1990 to
2010, but regardless, the number
of subjects referred for ESRD
treatment increased from 20,000 to
50,000 during this period because
of the increasing prevalence of
diabetes.2 The increasing popula-
tion at risk is a major determinant,
although also reduced mortality
from cardiovascular disease beforeCorrespondence: Peter Rossing, Steno
Diabetes Center Copenhagen, Niels
Steensens Vej 2, DK 2820 Gentofte,
Denmark. E-mail: peter.rossing@regionh.
dk
1362ESRD, and increased eligibility for
treatment of ESRD has contributed
to this, but it also reﬂects a need
for better prevention and treat-
ment of diabetic kidney disease
(DKD). Approximately 30% to
40% of subjects with diabetes
have chronic kidney disease and
conversely DKD is the leading
cause of ESRD in the Western
world. In addition to the risk for
ESRD, DKD is associated with a
signiﬁcantly increased risk for
cardiovascular disease, including
atherosclerotic cardiovascular dis-
ease, as well as heart failure.
To stop this epidemic of DKD,
prevention is of the utmost
importance. Prevention of diabetes
would be ideal, but the large and
growing population of subjects
with diabetes makes it necessary to
consider prevention of initiation or
progression of DKD in subjects
with established diabetes, being it
type 1 or type 2. Treatment of
overt DKD with risk factor control
and blockade of the renin angio-
tensin system has been recom-
mended for decades, and recent
studies suggest that new glucose-
lowering agents, such as sodium
glucose transporter 2 inhibitors
and perhaps glucagon-like peptide
1 receptor agonists, also will beKidney International Reports (2019) 4, 1362–1365helpful but will not solve the
problem.
Early prevention of micro-
albuminuria has been more difﬁ-
cult, although controlling glucose
seems useful, but difﬁcult to do
successfully, and quality assurance
data show that fewer than 15% are
at target for glucose, lipids, blood
pressure, and smoking.
Attempts to prevent initiation
of microalbuminuria with early
renin angiotensin system blockade
has given mixed results, with best
effect in hypertensive normoalbu-
minuric type 2 patients. For early
prevention to be successful, we
need better understanding of the
underlying pathophysiology.
Studying cohorts of patients at risk
for DKD, and identifying bio-
markers associated with risk for
progression, could provide us with
clues to the underlying processes
leading from uncomplicated dia-
betes to DKD. Such markers also
could provide targets for inter-
vention or markers used for iden-
tiﬁcation of high-risk subjects in
need of intensive risk factor con-
trol. Markers also may be useful
for monitoring the effect of tar-
geted interventions.
Randomized Olmesartan And
Diabetes MicroAlbuminuria Pre-
vention (ROADMAP) was a study
of 4447 subjects with type 2 dia-
betes and normal urinary albumin
excretion randomized to the
angiotensin II receptor blocker
olmesartan or placebo, and
demonstrated a small but signiﬁ-
cant reduction in progression to
microalbuminuria, which devel-
oped in 8.2% of the patients in the
olmesartan group (178 of 2160 pa-
tients) and 9.8% in the placebo
group (210 of 2139). Patients were
followed for an extended period,
and the cohort has now been used
for a study of biomarkers as
Figure 1. Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) biomarkers of microalbuminuria. ROADMAP has
identiﬁed 3 biomarkers, CXCL16, angiopoietin 2 (Ang2), and transforming growth factor beta 1 (TGFb1), as markers of progression to micro-
albuminuria, related to inﬂammation, endothelial cell/podocyte damage, and deposition of extracellular matrix, as indicated on the ﬁgure.
Modiﬁed with permission from Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease [published correction appears in Nat Rev Dis
Primers. 2015;1:15070]. Nat Rev Dis Primers. 2015;1:15018.4 GBM, glomerular basement membrane.
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microalbuminuria to teach us
about underlying pathophysiology
by selection of markers reﬂecting
different potential pathways,
including inﬂammation, ﬁbrosis,
endothelial dysfunction, and
vascular formation and damage.
The markers were studied in a
case-control subset of 172 patients
progressing to microalbuminuria,
with serum samples available
before progression, and a control
group of 188 matched controls.
The study tested 15 markers, and 3
were identiﬁed as independent risk
factors: CXCL16, angiopoietin 2, and
transforming growth factor b1.3
This would suggest that systemic
inﬂammation, extracellular matrix
remodeling, and angiogenesis-
related processes are important (see
Figure 14).
As discussed in their article,
both in preclinical and clinical
studies, systemic as well as local
inﬂammation has been identiﬁed as
an important process in theKidney International Reports (2019) 4, 1362–1365development of renal and cardio-
vascular complications in diabetes,
but it is difﬁcult to know if
increased markers of inﬂammation
are the cause of renal disease or are
a response to other processes un-
derlying the disease initiation. In
the current study, markers were
measured once at baseline, before
development of microalbuminuria,
but trajectories of inﬂammatory
markers were not studied. In a
group of normoalbuminuric sub-
jects with type 1 diabetes, repeated
measurements of markers of
inﬂammation and endothelial
dysfunction for 20 years demon-
strated a rise in most markers over
time, but inﬂammation was more
pronounced and preceded in-
creases in albuminuria even in the
normal range.5
Recently a kidney risk inﬂam-
matory signature in circulation
was described in a study of 3 dia-
betes cohorts predicting ESRD but
with more advanced DKD, illus-
trating how markers ofinﬂammation are increased both in
relation to initiation and progres-
sion of DKD.6 This marker
included several tumor necrosis
factor–related proteins, including
TNFR 1þ2, whereas these proteins
were not signiﬁcantly different
between cases and controls in the
ROADMAP study. Whether the
lack of overlap between markers
reﬂects the different platforms
used, different stages of disease, or
other factors is not clear. For
future studies it would be impor-
tant to standardize platforms
across studies and validate ﬁnd-
ings in multiple cohorts both in
terms of setting, stage of disease,
and populations, as well as impact
of interventions.
In relation to the dream of bio-
markers guiding us to useful
therapy, it is somewhat discour-
aging that 1 of the 3 signiﬁcant
markers, transforming growth
factor b1, has been targeted un-
successfully, as discussed in the
article, whereas MCP1, although1363
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cases and controls in the univariate
analysis did not make it as a pre-
dictor, but has been the target in
several studies with some effect on
albuminuria. In addition, VAP1,
which was not signiﬁcant between
groups, was also recently targeted
with success.7
The chemokine CXCL16 was 1
of the 3 biomarkers and at least
other chemokines have been tar-
geted with an albuminuria-
lowering effect.S1 One of the
largest studies targeting inﬂam-
mation in DKD was the Beacon
trial, and with bardoxolone
increasing estimated glomerular
ﬁltration rate, not affecting albu-
minuria but stopped because of
side effects.8 It may be important
that all the clinical intervention
studies were performed in early
or late established DKD and thus
were not preventive studies, and
although several studies reduced
albuminuria, the effect has generally
been modest with approximately
20% reduction in albuminuria.
The bardoxolone studies increased
estimated glomerular ﬁltration rate
but gave side effects before long-
term beneﬁts were demonstrated.
Pentoxifylline is a methylxan-
thine derivate and nonspeciﬁc
phosphodiesterase inhibitor with
anti-inﬂammatory, anti-
proliferative, and antiﬁbrotic ac-
tions in experimental studies. A
clinical study that successfully
targeted inﬂammation in DKD
with pentoxifylline demonstrated
a smaller decline in estimated
glomerular ﬁltration rate, which
after 2 years had decreased by a
mean  SEM of 2.1  0.4 ml/min
per 1.73 m2 in the pentoxifylline
group compared with 6.5  0.4
ml/min per 1.73 m2 in the control
group, with a between-group
difference of 4.3 ml/min per 1.73
m2 (95% conﬁdence interval 3.1
to 5.5 ml/min per 1.73 m2; P <13640.001) in favor of pentoxifylline.
The study was open label and did
not investigate progression to
ESRD or doubling of creatinine,
for which it was not powered,
which may explain why it is not
applied.S2
Whether prevention studies
targeting inﬂammation would be
successful is not known, and it
may be important to select nor-
moalbuminuric individuals with a
high risk, based on clinical risk
factors or biomarkers. As an
example of a study applying risk
markers for identiﬁcation for
intervention, the PRIORITY study
in normoalbuminuric type 2 dia-
betes applied the urinary
proteome–based risk factor
CKD273 to identify high-risk sub-
jects for progression to DKD, and
were subsequently targeted with
intervention (spironolactone or
placebo), thus the study targeted
ﬁbrosis, not inﬂammation, but il-
lustrates enrichment of high-risk
candidates.9
When added to the clinical
characteristics, the 3 biomarkers
were able to increase receiver
operating characteristic area under
the curve from 0.638 to 0.760,
which was highly signiﬁcant. It is,
however, important to recall that
the effect of clinical characteristics
may be difﬁcult to interpret in a
study in which the cases and
controls were very carefully
matched for multiple risk factors at
baseline, and the area under the
curve in a case-control study with
almost 50% progressors and 50%
controls cannot be applied in a
clinical setting, as in the ROAD-
MAP study only 8% to 10% were
progressors, thus false-positives
and false-negatives would be very
different if the markers were used
to identify progressors
In conclusion, the substudy
from ROADMAP has provided new
signs leading us in the direction ofKearly DKD. The future will tell if
they will be useful as risk markers
or also as identiﬁed targets.
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